Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery

ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy

Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy

FDA Perspectives on the Use of Liquid Biopsy in NSCLC

Biopsy Options Create New Decision-making Points for Clinicians

The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma

Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role

Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status

First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC

Managing lung cancer in the time of COVID-19

Leora Horn, MD - IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD - IASLC Virtual Presidential Symposium Presentation